LINDY CHAPMAN: Open Payments
NPI 1992375877 · CANTON, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$659 in 35 payments from 17 companies in 2025. Trend: 2023 $1,425 · 2024 $991 · 2025 $659
Food & beverage: $659
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $158 |
| ABBVIE INC. | 10 | $139 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| Lundbeck LLC | 2 | $34 |
| Fidia Pharma USA Inc. | 2 | $33 |
| Novo Nordisk Inc | 2 | $30 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Amgen Inc. | 1 | $20 |
Products named: FARXIGA, UBRELVY, REXULTI, QULIPTA, AIRSUPRA, GEMTESA, HYMOVIS, CAPLYTA.
Industry payments across NY — which companies pay providers there.
